Toggle Main Menu Toggle Search

Open Access padlockePrints

Recombinant activated factor VII (rFVIIa/NovoSeven®) in intractable haemorrhage: Use of a clinical scoring system to predict outcome

Lookup NU author(s): Dr Tina Biss, Dr John Hanley


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Background and Objectives: Recombinant activated factor VII (rFVIIa/NovoSeven®) has been advocated in the treatment of life-threatening haemorrhage, but appropriate clinical indications remain uncertain. The aim of this study was to detect factors predictive of outcome and to incorporate them into a prognostically significant scoring system. Materials and Methods: Thirty-six patients received rFVIIa for uncontrolled surgical, traumatic or obstetric bleeding in the Northern Region of the UK over a 45-month period. Clinical, laboratory and outcome data were examined. Characteristics of survivor and non-survivor groups were compared. A prognostic scoring system was evaluated retrospectively according to the presence of coagulopathy, renal impairment, hypothermia, greater than 10 units of red cell transfusion, advanced age and obstetric indication, with patients allocated to low, intermediate and high-risk groups. Results: Clinical response occurred in 26 patients (72%) with a reduction in prothrombin time and blood product requirements. Death occurred in 19 (53%). Four patients (11%) suffered thrombotic events. Survivors were younger than non-survivors and less likely to have coagulopathy, renal impairment or hypothermia at the time of administration. Survivors were more likely to have had an initial clinical response in terms of an immediate reduction in haemorrhage. Non-survivors were transfused a greater number of red cell units prior to administration. Survival varied according to prognostic score; low-risk patients had a survival rate of 85%, intermediate-risk patients had a survival rate of 50% and high-risk patients had a survival rate of 18%. Conclusions: FVIIa has a role in the cessation of haemorrhage, but may not improve survival. Use of a clinical scoring system may help to predict outcome. © 2005 Blackwell Publishing.

Publication metadata

Author(s): Biss TT, Hanley JP

Publication type: Article

Publication status: Published

Journal: Vox Sanguinis

Year: 2006

Volume: 90

Issue: 1

Pages: 45-52

ISSN (print): 0042-9007

ISSN (electronic): 1423-0410

Publisher: Wiley-Blackwell


DOI: 10.1111/j.1423-0410.2005.00711.x

PubMed id: 16359355


Altmetrics provided by Altmetric